Bradford Teaching Hospitals NHS Foundation Trust adopts ZedScan

Tuesday 10th November 2020

Bradford Teaching Hospitals receive ZedScan™ funding from cancer charity, Michelle Henderson Cervical Cancer Trust


10 November 2020

Zilico Ltd is pleased to announce that Bradford Teaching Hospitals NHS Foundation Trust has received funding from the Michelle Henderson Cervical Cancer Trust, to allow them to introduce ZedScan™ to further improve the diagnosis of cervical cancer in women referred to its colposcopy clinics at Bradford Royal Infirmary.

Using patented Electrical Impedance Spectroscopy (EIS) platform technology, ZedScan is used (as an adjunct to coloscopy) to detect cervical abnormalities (pre-cancerous changes) before they develop into cervical cancer.

Having sadly lost his 28-year-old daughter to cervical cancer in 2012, ex-Scotland football international William “Willie” Henderson, has been a key fundraiser for the charity she set up when she was diagnosed with the disease. The charity raises awareness and funding for hospital gynaecology equipment, as a way to thank those who helped Michelle during her treatment and ensure women are diagnosed and treated with state-of-art technology.

The Michelle Henderson Cervical Cancer Trust has also funded ZedScan devices for hospitals in Aberdeen and Dundee, Scotland. Willie is pleased that they are now enabling women in Bradford and surrounding areas to benefit from this technology and says: “It has been an honour to be able to fund the ZedScan device for Bradford Royal Infirmary in Michelle’s memory, her vision in setting up the charity was for moments like this.” 

Following a service evaluation, Bradford Teaching Hospitals found ZedScan increased the detection of high-grade disease (which has the potential to become cancerous) and helped inform clinical treatment decisions. The high sensitivity of the ZedScan device also gives clinicians the confidence to discharge women to surveillance or routine screening when no disease is present. Results from the evaluation demonstrate a potential to achieve the vital value propositions of better patient outcomes and positive health economics for the Trust.

The clinical team at the Trust is enthusiastic about bringing ZedScan to its colposcopy service.

Lead clinician for the colposcopy unit, Consultant Gynaecologist and Treasurer of the British Society for Colposcopy and Cervical Pathology (BSCCP) Mr Nick Myerson, said: “During the COVID pandemic, cancer care and prevention services have remained a priority for Bradford Teaching Hospitals.

“Within colposcopy, it is essential that we are able to confidently diagnose cervical abnormalities and make the best decision for patients at their first visit. The introduction of ZedScan to our services will support us in achieving this and we are extremely grateful to Mr Henderson and the Michelle Henderson Cervical Cancer Trust for this donation to the hospital.”


Notes for editors


About Zilico Limited (Manufacturers of ZedScan™)

Zilico was founded in 2006 following a successful collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN). Zilico's head office is located in Manchester, UK. Manufacturing and R&D functions are also carried out in the UK.

Many diseases still rely on visual diagnosis by a clinician. Zilico has developed a technology which recognises the changes in tissue structure using the electrical properties of cells. This non-visual technique promotes early detection, allowing the clinician to use appropriate intervention which can prevent the disease from further progression.

The company has developed its patented Electrical Impedance Spectroscopy (EIS) into a platform technology for cancer diagnosis and is expanding its product development into other clinical areas.

About ZedScan

ZedScan, Zilico’s flagship product, a diagnostic in the cervical cancer pathway, is now in routine use across several NHS hospitals.  The ability to correctly identify those women who have, and those who do not have disease is pivotal to the success of any screening programme. ZedScan has demonstrated greater accuracy in detecting cervical disease and supports better management of patients.

Two key value propositions that the NHS seek are provided with ZedScan in routine use; improved health economics and better patient outcomes. The improved health economics benefit both the payer and service provider, making ZedScan extremely valuable in the current NHS financial climate. Together, these value propositions support a healthier future for the NHS.

Cervical Cancer

Cervical cancer is the 4th most common cancer in women globally and the 14th most common cancer in the UK with 3,200 new cases diagnosed each year and is responsible for 270,000 deaths annually worldwide. The disease can be treated if diagnosed early, particularly at the pre-cancerous or cervical intra-epithelial neoplasia (CIN) stage.

About Bradford Teaching Hospitals NHS Foundation Trust

Bradford Teaching Hospitals NHS Foundation Trust provides gynaecology and colposcopy services on its Women's and Newborn Unit at Bradford Royal Infirmary.

The Trust is responsible for providing hospital services for the people of Bradford and communities across Yorkshire. It serves a core population of around 500,000 and provides specialist services for 1.1 million people.

As a teaching Trust, it is at the forefront of education and development in healthcare, and has an excellent reputation for research performance. It is one of the leading centres in conducting applied research in the country.

In 2019 the Trust became the first healthcare trust in Europe to open an artificial intelligence (AI)-led Command Centre to reduce waiting times and make the experience of being in hospital smoother, faster and more efficient for patients.

About the Michelle Henderson Cervical Cancer Trust
Michelle set up the organisation herself in 2010, in the hope of raising awareness and funds towards hospital equipment, medicines and support for anyone diagnosed with the disease.

Michelle Henderson was just 26 when she was diagnosed with cervical cancer. The diagnosis came as a shock to her whole family including her father, ex-Scotland football legend William “Willie” Henderson. Tragically, Michelle died of the disease just two years later in 2012, on her 28th birthday. Since his daughter’s diagnosis, Willie has been a key fundraiser for the Michelle Henderson Cervical Cancer Trust.


COVID-19 is a new infectious respiratory virus which spreads primarily through droplets generated when an infected person coughs or sneezes, or through droplets of saliva or discharge from the nose. It's caused by a type of virus called coronavirus. To protect yourself, clean your hands frequently with an alcohol-based hand rub or wash them with soap and water. At this time, there are no specific vaccines or treatments for COVID-19.

Everyone must follow Government advice to help stop coronavirus (COVID-19) spreading.

Do not leave home if you or anyone in your household has symptoms.

For updated information and guidance visit: